Publications by authors named "T I Panchenko"
Article Synopsis
- Antibody responses are crucial for defending against SARS-CoV-2 by stopping the virus from entering cells, and a new assay called 2D-MBBA has been developed to measure various antibody isotypes simultaneously.
- This assay was used to analyze IgG, IgM, and IgA levels against the spike protein and its variants, and machine learning significantly improved predictions of how well these antibodies neutralize the virus in convalescent patients.
- The method can differentiate between antibody profiles in convalescent and vaccinated individuals and offers the potential for rapid testing of neutralization efficacy against new variants and pathogens using just a small blood sample.
Article Synopsis
- - Understanding antibody responses to SARS-CoV-2 is crucial for effective COVID-19 containment strategies; however, predicting neutralization capacity remains challenging, as convalescent patients show variable outcomes.
- - A study examined sera from 101 recovered healthcare workers, revealing sustained IgG levels against SARS-CoV-2 proteins, but most individuals had low neutralization ability, with only 6% demonstrating high neutralizing titers.
- - Findings suggest that possessing a variety of antibody isotypes (IgG, IgM, IgA) correlates with stronger neutralization responses, indicating that a broader antibody repertoire may enhance SARS-CoV-2 neutralization effectiveness.
J Immunol Methods
March 2021
Article Synopsis
- The study focuses on developing a cost-effective multiplex bead binding assay (MBBA) for analyzing protein-ligand interactions without the need for specialized equipment or expensive reagents.
- The method innovatively uses biotin-streptavidin interactions and fluorescently labeled magnetic beads to enhance experimental throughput.
- The effectiveness of this new MBBA method is demonstrated by characterizing antibodies against SARS-CoV-2, significantly improving efficiency and reducing the amount of antigen required compared to traditional methods.
Article Synopsis
- * Research on convalescent sera from COVID-19 patients showed that only a small number of antibodies specifically targeted the ACE2-interacting surface on the spike protein, indicating potential immune evasion by the virus.
- * Selection experiments revealed that while unbiased approaches favored antibodies targeting regions away from ACE2IS, biased methods successfully identified ACE2IS-binding antibodies, suggesting that the ACE2IS has evolved to be less immunogenic, which is key for vaccine development.
Article Synopsis
- - The COVID-19 pandemic is a persistent global challenge, where host immunity is crucial for protection, with the spike protein on SARS-CoV-2 being a key target for neutralizing antibodies through its interaction with the ACE2 receptor.
- - Research involving an RBD mutant showed that only a small portion of antibodies from recovered COVID-19 patients targeted the critical ACE2-interacting surface, indicating limited immune recognition of this viral component.
- - Different antibody selection methods revealed that while unbiased selection favored regions outside the ACE2IS, biased selection was effective in identifying ACE2IS-targeting antibodies, suggesting that the ACE2IS is less immunogenic, which is significant for future vaccine development.
